

EGFR Antibody (Y869)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7628h

Product Information

Application WB, E **Primary Accession** P00533 **Other Accession** Q01279 Reactivity Human **Predicted** Mouse Host Rabbit Clonality Polyclonal Isotype Rabbit IgG **Clone Names** RB10970 134277 **Calculated MW** 847-876 **Antigen Region**

Additional Information

Gene ID 1956

Other Names Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor

tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1

Target/SpecificityThis EGFR antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 847-876 amino acids from human

EGFR.

Dilution WB~~1:1000 E~~Use at an assay dependent concentration.

Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is purified through a protein A column, followed by peptide

affinity purification.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions EGFR Antibody (Y869) is for research use only and not for use in diagnostic or

therapeutic procedures.

Protein Information

Name EGFR (HGNC:3236)

Synonyms ERBB, ERBB1, HER1

Function

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed: 10805725, PubMed: 27153536, PubMed: 2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF- alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding triggers receptor homoand/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed: 11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Endosome. Endosome membrane. Nucleus. Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055)

Tissue Location

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.


Background

EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.


References

Aifa, S., et al., Exp. Cell Res. 302(1):108-114 (2005). Adams, T.E., et al., Growth Factors 22(2):89-95 (2004). Ichinose, J., et al., Biochem. Biophys. Res. Commun. 324(3):1143-1149 (2004). Kuribayashi, A., et al., Endocrinology 145(11):4976-4984 (2004). Kapoor, G.S., et al., Mol. Cell. Biol. 24(2):823-836 (2004).

Images



All lanes: Anti-EGFR Antibody (Y869) at 1:1000 dilution Lane 1: A431 whole cell lysate Lane 2: MDA-MB-231 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size: 134 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



Western blot analysis of EGFR (arrow) using rabbit polyclonal EGFR Antibody (Cat.#AP7628h).293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the EGFR gene (Lane 2) (Origene Technologies).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.